Zobrazeno 1 - 10
of 231
pro vyhledávání: '"R A Ivanov"'
Autor:
S A Tyulyandin, M Yu Fedyanin, T Yu Semiglazova, V M Moiseenko, S V Odintsova, B Ya Alekseev, R A Ivanov, M S Shustova
Publikováno v:
Современная онкология, Vol 19, Iss 3, Pp 5-12 (2017)
Purpose. To evaluate pharmacokinetics, pharmacodynamics, safety, immunogenicity and efficacy of intravenous infusions of BCD-100 (JSC “BIOCAD”, Russia) in increasing doses. Patients (materials) and methods. Patients with advanced malignant tumors
Externí odkaz:
https://doaj.org/article/6751069bb31a44e7bf9f32138fa3a1cd
Autor:
E O Ignatova, O N Burdaeva, M V Kopp, B N Kotiv, D P Udovitsa, D L Stroiakovskii, S M Alekseev, L P Sheveleva, A V Khorinko, Iu S Shapovalova, V M Moiseenko, R A Ivanov
Publikováno v:
Современная онкология, Vol 18, Iss 2, Pp 39-47 (2016)
Objective. Within the multi-center double-blind randomized clinical study, investigate the bioequivalence (immediate efficacy, safety and pharmacokinetics) of BCD-022 (trastuzumab, JSC BIOCAD, Russia), as compared with Herceptin® (trastuzumab, F.Hof
Externí odkaz:
https://doaj.org/article/a2ddfb29e90a4971a38b8f7e9b03b151
Autor:
P V Krivorotko, O N Burdaeva, M N Nechaeva, M A Frolova, M V Kopp, A A Abrosimova, R A Ivanov
Publikováno v:
Современная онкология, Vol 17, Iss 2, Pp 45-52 (2015)
Objectives: to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2). Methods. 135 patients with breast cancer
Externí odkaz:
https://doaj.org/article/e4910dad52da48c08d84697f09d2e30f
Autor:
A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya
Publikováno v:
RUDN Journal of Medicine, Vol 0, Iss 2, Pp 114-118 (2014)
Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin. A necessity to develop new medications and to
Externí odkaz:
https://doaj.org/article/b3f82f65f8ea486bb2df1ec42ad50214
Publikováno v:
Современная онкология, Vol 16, Iss 2, Pp 38-44 (2014)
This article contains the detailed analysis of current approach to non-clinical and clinical development of monoclonal antibody biosimilars which is described in current guidelines of the European Medicines Agency (2012). Requirements of European reg
Externí odkaz:
https://doaj.org/article/0f759e734ec246f9b97f065efee445d1
Publikováno v:
Nauka ta progres transportu, Iss 1(105), Pp 62-83 (2024)
Implementation of Innovative Technologies During The Modernization of Existing Level Crossings for High-Speed Train Traffic Purpose. The main purpose of the study is to review innovative technologies for improving safety at the intersection of rai
Externí odkaz:
https://doaj.org/article/2a7828f1ed5e4ca9a7073f8995baf53c
Autor:
R. A. Ivanov, S. A. Lashin
Publikováno v:
Вавиловский журнал генетики и селекции, Vol 27, Iss 7 (2023)
Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic alterations that drive uncontrolled cell growth and proliferation. Evolutionary dynamics plays a crucial role in the emergence and development of tumors, shapi
Externí odkaz:
https://doaj.org/article/7623980b74af4aca8b7f3a73531aa87b
Publikováno v:
Медицинская иммунология, Vol 24, Iss 3, Pp 587-596 (2022)
Purinergic signaling modulates systemic and local inflammatory responses in immune-mediated and autoimmune diseases, including psoriasis. Extracellular ATP is an important factor of purinergic regulation, and its levels are regulated by catalytic eff
Externí odkaz:
https://doaj.org/article/e7e91f12253b4ecbb1f0fcca3c73f34b
Autor:
R. Yo. Maksvitis, R. V. Ivanov, A. V. Amelin, A. V. Goncharova, A. S. Andreeva, I. A. Grinyov
Publikováno v:
Эпидемиология и вакцинопрофилактика, Vol 18, Iss 6, Pp 45-52 (2020)
Relevance. The absence of a registered vaccine against G145R escape mutant determines the need to develop a drug for the prophylaxis of infectious hepatitis caused by the hepatitis B virus.The aim of the study was to evaluate the safety and reactogen
Externí odkaz:
https://doaj.org/article/f4301b7bb6de4775b00ff4374eed95f0
Autor:
Т. V. Korotaeva, A. V. Samtsov, A. L. Bakulev, M. M. Kokhan, I. K. Minullin, O. A. Vylegzhanina, V. V. Dubensky, B. V. Khalilov, A. A. Khotko, O. S. Zykova, I. V. Chumachenko, A. M. Lukyanov, A. V. Artemyeva, S. I. Derbin, E. Yu. Stukalina, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Современная ревматология, Vol 12, Iss 4, Pp 71-84 (2018)
The paper gives the results of the phase III clinical trial of adalimumab (ADA) biosimilar, (BCD-057) (BIOCAD, Russia), which demonstrate the clinical equivalence of the biosimilar to the ADA innovator Humira® in patients with moderate and severe ps
Externí odkaz:
https://doaj.org/article/dcfec1eedb564d51b6a28f18e8c990d5